Loading...
Loading...
Curated peer-reviewed research with clinical relevance annotations for healthcare providers
Jastreboff AM, Aronne LJ, et al. • New England Journal of Medicine (2022)
Tirzepatide represents a new standard for pharmacological obesity treatment. Dual GIP/GLP-1 mechanism appears more effective than GLP-1 alone.
Wilding JPH, Batterham RL, et al. • New England Journal of Medicine (2021)
Establishes semaglutide 2.4mg weekly as highly effective for obesity treatment. NNT of ~2 for clinically meaningful weight loss.
GI side effects common. Long-term data beyond 68 weeks still emerging.
Gwyer D, Wragg NM, Wilson SL • Journal of Orthopaedic Surgery and Research (2019)
Strong preclinical rationale for BPC-157 in tendon injuries. Human RCTs needed but clinical experience supports efficacy.
Most evidence from animal studies. Human clinical trials limited.
Kingsberg SA, et al. • Obstetrics & Gynecology (2019)
FDA-approved for premenopausal HSDD. First-line pharmacotherapy option after ruling out contributing factors.
Sikiric P, et al. • Current Pharmaceutical Design (2018)
Oral BPC-157 may be beneficial for GI healing. Consider for patients with NSAID gastropathy or IBD.
Human dose-finding studies needed. Optimal oral dosing unclear.
Gauthier S, Proaño JV, et al. • Dementia and Geriatric Cognitive Disorders (2015)
Level A evidence supports Cerebrolysin for mild-moderate dementia. Consider for patients who haven't responded to cholinesterase inhibitors.
Heiss WD, Brainin M, et al. • Stroke (2012)
Consider Cerebrolysin as adjunctive therapy in moderate acute ischemic stroke, particularly when started early.
Primary endpoint not met in ITT analysis. Benefits seen in pre-specified subgroups.
Zozulia AA, et al. • Bulletin of Experimental Biology and Medicine (2008)
Selank offers anxiolysis without benzodiazepine side effects. Consider for patients who need anxiety relief but must remain cognitively sharp.
Agapova TY, et al. • Doklady Biological Sciences (2007)
Provides mechanistic basis for cognitive benefits. BDNF upregulation supports neuroplasticity claims.
Animal study. Human neuroimaging studies would strengthen evidence.
Falutz J, et al. • JAMA (2007)
Only FDA-approved GHRH analog. Level A evidence for visceral fat reduction. Consider for non-HIV patients with visceral adiposity.
You J, et al. • Journal of Viral Hepatitis (2006)
Approved for HBV in multiple countries. Consider as adjunct to standard HBV therapy or for immunocompromised patients.
Gusev EI, Skvortsova VI, et al. • Zhurnal Nevrologii i Psikhiatrii (2005)
Supports use of Semax in acute stroke recovery. Russian regulatory approval based on this evidence.
Single-center study. Needs replication in Western populations.
Bock-Marquette I, et al. • Nature (2004)
Provides rationale for TB-500 in tissue repair. Cardiac applications under investigation. Use caution with angiogenesis in cancer history.
Animal study. Human cardiac trials in early stages.
Raun K, Hansen BS, et al. • European Journal of Endocrinology (1998)
Establishes Ipamorelin as the most selective GHRP. Preferred for patients concerned about cortisol or appetite effects.